Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?

• September 18, 2026

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

• September 16, 2026

• 2 min

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

• by Jie Mei, Guanyu Jiang, Yundi Chen, Yongrui Xu, Yuan Wan, Ruo Chen, Feng Liu, Wenjun Mao, Mingfeng Zheng, Junying Xu

• September 17, 2026

The Pitfalls of Disproportionality Analysis: Insights on Their Interwoven Complexity and a Front-End Mitigation Strategy

• by Manfred Hauben, Rave Harpaz, Robert Weber

• September 17, 2026